Экономическая эффективность лечения пациентов с постоянной формой мерцательной аритмией Аценокумаролом, с использованием фармакогенетического тестирования

BACKGROUND. Acenocoumarol is the global standard of anticoagulant therapy, but often treatment with acenocoumarol accompanied by adverse drug reactions. Model of personalized medicine, actively developing now, can reduce the number of side effects during therapy of Acenocoumarol, mainly due to individual genetic characteristics (polymorphisms of genes CYP2C9 and VKORC1). This will help to reduce side effects of therapy and reduce treatment costs.